Guideline for antibacterial therapy of adult community-acquired pneumonia in the emergency department under the physicianpharmacist collaborative management model

Abstract

Community-acquired pneumonia (CAP) in adults (⩾18 years old) is the most common infectious disease encountered in emergency departments. Its clinical complexity and the need for prompt treatment decisions pose significant challenges for patient management. The physician-pharmacist collaborative management (PPCM) model, which optimizes drug therapy regimens through collaboration between physicians and clinical pharmacists, has demonstrated strong clinical value in practice. However, the lack of standardized national guidelines for the application of the PPCM model in emergency departments in China has hampered its widespread adoption. This guideline is developed based on evidence-based medicine and clinical practice experience, with a focus on the application of the PPCM model in the management of CAP in emergency settings. It outlines the significance of the PPCM model, its applicable scenarios, the respective roles of emergency physicians and clinical pharmacists, and its practical implementation in the antimicrobial treatment of CAP patients. In addition, the guideline proposes standardized implementation processes and clinical pathways. By promoting the PPCM model, the expert panel aims to standardize the use of antimicrobial agents in the emergency treatment of CAP, reduce the risk of antimicrobial resistance, and improve patient outcomes.

Keywords

Community-acquired pneumonia / Emergency / Physician-pharmacist collaborative management / Clinical pharmacists / Antibacterial therapy

Conflict of interest statement

Chuan-Zhu Lv is an Editor-in-Chief of Journal of Acute Disease, Yu Cao is an Editorial Board Member of Journal of Acute Disease, and Jin-Jin Liu is a Managing Editor of Journal of Acute Disease. The article was subject to the journal’s standard procedures, with peer review handled independently of this Editor-in-Chief, this Editorial Board Member and this Managing Editor, and their research groups. The authors declare no conflict of interest.

Funding

This work was supported by Sanming Project of Medicine in Shenzhen (No.SZZYSM202411012) and Beijing Clinical Key Specialty Project (2023).

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Roman C, Edwards G, Dooley M, Mitra B. Roles of the emergency medicine pharmacist: A systematic review. Am J Health Syst Pharm 2018; 75(11):796-806.

[2] Regulations of pharmacy affairs for medical institutions. Chin Pharm 2011; 8(3):41-44.

[3] Pan C, Pang JJ, Cheng K, Xu F, Chen YG. Trends and challenges of emergency and acute care in Chinese mainland: 2005-2017. World J Emerg Med 2021; 12(1):5-11.

[4] Wang Z, Xiong X, Wang S, Yan J, Springer M, Dellinger RP. Causes of emergency department overcrowding and blockage of access to critical services in Beijing:A 2-year study. J Emerg Med 2018; 54(5):665-673.

[5] Rodrigo C, Mckeever TM, Woodhead M, Welham S, Lim WS. Admission via the emergency department in relation to mortality of adults hospitalised with community-acquired pneumonia: An analysis of the British Thoracic Society national community-acquired pneumonia audit. Emerg Med J 2015; 32(1):55-59.

[6] Liu M, Liu JF. Methodology and application of the Chinese cerebrovascular disease guidelines. Chin J Neurol 2015; 48(4):241-245.

[7] Lüthi-Corridori G, Roth AI, Boesing M, Jaun F, Tarr PE, Leuppi-Taegtmeyer AB, et al. Diagnosis and therapy of community-acquired pneumonia in the emergency department: A retrospective observational study and medical audit. J Clin Med 2024; 13(2):574.

[8] Lorentzen MH, Rosenvinge FS, Lassen AT, Graumann O, Laursen CB, Mogensen CB, et al. Empirical antibiotic treatment for community-acquired pneumonia and accuracy for Legionella pneumophila, Mycoplasma pneumoniae, and Clamydophila pneumoniae: A descriptive cross-sectional study of adult patients in the emergency department. BMC Infect Dis 2023; 23(1):580.

[9] Jones BE, Chapman AB, Ying J, Rutter ED, Nevers MR, Baker A, et al. Diagnostic discordance, uncertainty, and treatment ambiguity in community-acquired pneumonia: A national cohort study of 115 U.S. veterans affairs hospitals. Ann Intern Med 2024; 177(9):1179-1189.

[10] Ruiz-Ramos J, Escolà-Vergé L, Monje-López ÁE, Herrera-Mateo S, Rivera A. The interventions and challenges of antimicrobial stewardship in the emergency department. Antibiotics (Basel) 2023; 12(10):1522.

[11] Zhao HY, Bian JM, Zhuo L, Wang MM, Sun F, Zhang M, et al. Antibiotic use in emergency departments of class III general hospitals in China. Chin J Epidemiol 2018; 39(7):959-965.

[12] Cartuliares MB, Søgaard SN, Rosenvinge FS, Mogensen CB, Hertz MA, Skjøt-Arkil H. Antibiotic guideline adherence at the emergency department: A descriptive study from a country with a restrictive antibiotic policy. Antibiotics (Basel) 2023; 12(12):1680.

[13] Kang SH, Jo YH, Lee JH, Jang DH, Kim YJ, Park I. Antibiotic prescription consistent with guidelines in emergency department is associated with 30-day survival in severe community-acquired pneumonia. BMC Emerg Med 2021; 21(1):108.

[14] Tubiana S, Epelboin L, Casalino E, Naccache JM, Feydy A, Khalil A, et al. Effect of diagnosis level of certainty on adherence to antibiotics’ guidelines in ED patients with pneumonia: A post-hoc analysis of an interventional trial. Eur J Emerg Med 2023; 30(2):102-109.

[15] Kulwicki BD, Brandt KL, Wolf LM, Weise AJ, Dumkow LE. Impact of an emergency medicine pharmacist on empiric antibiotic prescribing for pneumonia and intra-abdominal infections. Am J Emerg Med 2019; 37(5):839-844.

[16] Kooda K, Canterbury E, Bellolio F. Impact of pharmacist-led antimicrobial stewardship on appropriate antibiotic prescribing in the emergency department: A systematic review and meta-analysis. Ann Emerg Med 2022; 79(4):374-387.

[17] Iovino G, Nadeau L. Effect of pharmacist-initiated interventions on duration of antibiotic therapy for acute exacerbation of chronic obstructive pulmonary disease and community-acquired pneumonia. Can J Hosp Pharm 2023; 76(4):296-301.

[18] Rainess RA, Patel VV, Cavanaugh JB, Hill J. Evaluating the addition of a clinical pharmacist service to a midlevel provider-driven culture follow-up program in a community emergency department. J Pharm Technol 2021; 37(3):140-146.

[19] Johnsgård T, Elenjord R, Holis RV, Waaseth M, Zahl-Holmstad B, Fagerli M, et al. How much time do emergency department physicians spend on medication-related tasks? A time-and-motion study. BMC Emerg Med 2024; 24(1):56.

[20] Nymoen LD, Tran T, Walter SR, Lehnbom EC, Tunestveit IK, Øie E, et al. Emergency department physicians’ distribution of time in the fast paced-workflow-a novel time-motion study of drug-related activities. Int J Clin Pharm 2022; 44(2):448-458.

[21] Saito Y. Effects of emergency room-specialized pharmacists on emergency medicine. Yakugaku Zasshi 2023; 143(8):623-628.

[22] General Office of the National Health Commission, Office of the National Administration of Traditional Chinese Medicine, General Office of the Logistics Support Department of the Central Military Commission. Notice on issuing the prescription review standards for medical institutions. Gazette of the National Health and Family Planning Commission of People’s Republic of China 2018;7:35-38.

[23] Li WR, Li D, Zhao CJ, Qian Y. Current situation analysis of pre-prescription review in medical institutions in China. China Pharm 2021; 32(5):524-529.

[24] Heng ST, Wong J, Young B, Tay HL, Tan SH, Yap MY, et al. Effective antimicrobial stewaRdship strategIES (ARIES): Cluster randomized trial of computerized decision support system and prospective review and feedback. Open Forum Infect Dis 2020; 7(7):ofaa254.

[25] China Hospital Association Pharmaceutical Affairs Committee Medical Institution Pharmaceutical Service Practices Writing Group. Medical institution pharmaceutical service practices. Her Med 2019; 38(12):1535-1556.

[26] Li Z, Cheng B, Zhang K, Xie G, Wang Y, Hou J, et al. Pharmacist-driven antimicrobial stewardship in intensive care units in East China: A multicenter prospective cohort study. Am J Infect Control 2017; 45(9):983-989.

[27] Arenz L, Porger A, De Michel M, Weber A, Jung J, Horns H, et al. Effect and sustainability of a stepwise implemented multidisciplinary antimicrobial stewardship programme in a university hospital emergency department. JAC Antimicrob Resist 2024; 6(1):dlae026.

[28] Chen ZZ, Zhen JC, Lyu QZ, Jiang L, Lu XY, Zhang ZQ, et al. Development and analysis of management standards for clinical application of antimicrobial drugs. Her Med 2024; 43(8):1222-1225.

[29] Chinese Hospital Association. T/CHAS 20-4-12-2-2023 Pharmaceutical administration and pharmaceutical practice in healthcare institutions Part 4-12-2: Pharmaceutical affairs-clinical medication management - antimicrobial agents 2023: Beijing

[30] Zhang J, Qian X, Zhang L, Hu L, Fan L, Wang Q, et al. Evaluation of the effectiveness of clinical pharmacists’ consultation in the treatment of infectious diseases: A single-arm, prospective cohort study. Front Pharmacol 2019;10:187.

[31] Zhang J, Li X, He R, Zheng W, Kwong JS, Lu L, et al. The effectiveness of clinical pharmacist-led consultation in the treatment of infectious diseases: A prospective, multicenter, cohort study. Front Pharmacol 2020;11:575022.

[32] Wang Q, Zhan SP, Xia PY, Wang Z, Gao S, Xu YG, et al. Formulation and analysis of pharmaceutical consults services standards. Her Med 2023; 42(11):1626-1630.

[33] Chinese Hospital Association. T/CHAS 20-2-10-2022 Pharmaceutical administration and pharmaceutical practice in healthcare institutions part 2-10: Clinical pharmaceutical service-pharmaceutical case discussion 2023: Beijing

[34] Tang YM, Zhao M. Pharmacists participating in consultation to guide rational use of drugs for infectious diseases and case summary analysis. J Pract Med 2017; 34(3):240-243.

[35] Pan LL, Wu DW, Liu SS, Pang J, Zou XZ. Application of multi-disciplinary team model in the management of hospital antimicrobial management. Chin J Infect Control 2024; 23(6):719-724.

[36] Pulia M, Redwood R, May L. Antimicrobial stewardship in the emergency department. Emerg Med Clin North Am 2018; 36(4):853-872.

[37] Taylor RA, Sangal RB, Smith ME, Haimovich AD, Rodman A, Iscoe MS, et al. Leveraging artificial intelligence to reduce diagnostic errors in emergency medicine: Challenges, opportunities, and future directions. Acad Emerg Med 2025; 32(3):327-339.

[38] Preiksaitis C, Ashenburg N, Bunney G, Chu A, Kabeer R, Riley F, et al. The role of large language models in transforming emergency medicine: Scoping review. JMIR Med Inform 2024;12:e53787.

[39] Ministry of Health of the People’s Republic of China. Notice on issuing the guidelines for the construction and management of emergency departments (trial). Gazette of the Ministry of Health of the People’s Republic of China 2009;7:30-34.

[40] Zhang WW, Li ZL, Xing YH, Chen B, Ma YF, Lv CZ. Expert consensus on the construction of emergency departments in Chinese county-level hospitals. Chin J Crit Care Med 2019; 39(5):401-407.

[41] Ministry of Health of the People’s Republic of China. Measures for the administration of clinical use of antibacterials. Chin J Infect Contr 2012; 11(3):236-240.

[42] Respiratory Equipment Technical Committee of China Association of Medical Equipment Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Guangdong Pharmaceutical Association. Expert consensus on physician-pharmacist collaborative management of stable chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis 2022; 45(10):980-987.

[43] Xia YZ, Chen J, Wei L, Chen P, Tang KJ. Expert consensus on physicians-pharmacists collaborative drug therapy management (CDTM). Pharmacy Today 2024; 34(12):888-892.

[44] Sadeq AA, Hasan SS, Aboukhater N, Conway BR, Abdelsalam AE, Shamseddine JM, et al. Exploring antimicrobial stewardship influential interventions on improving antibiotic utilization in outpatient and inpatient settings: A systematic review and meta-analysis. Antibiotics (Basel) 2022; 11(10):1306.

[45] Sichuan Provincial People’s Hospital Department of Pharmacy, School of Medicine, University of Electronic Science and Technology of China, Clinical Pharmacy Branch of Chinese Medical Association, Tong RS. Practice guideline for the value evaluation of clinical pharmacy services (First Edition). Her Med 2024; 43(3):321-333.

[46] Ortmann MJ, Johnson EG, Jarrell DH, Bilhimer M, Hayes BD, Mishler A, et al. ASHP guidelines on emergency medicine pharmacist services. Am J Health Syst Pharm 2021; 78(3):261-275.

[47] Chongqing Pharmaceutical Association, The Drafting Team of Expert Consensus on Pharmaceutical Active Consultation Service in Medical Institutions, Du Q, Liu SQ. Expert consensus on pharmaceutical active consultation service in medical institutions. Chin Pharm 2024; 35(23):2837-2843.

[48] Chinese Medical Association Emergency Medicine Branch, Chinese Expert Consensus Group on Emergency Diagnosis and Treatment of Community-Acquired Pneumonia in the Elderly. Chinese expert consensus on emergency diagnosis and treatment of community-acquired pneumonia in the elderly. Chin J Emerg Med 2023; 32(10):1319-1327.

[49] Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet 2021; 398(10303):906-919.

[50] Vaughn VM, Dickson RP, Horowitz JK, Flanders SA. Community-acquired pneumonia: A review. JAMA 2024; 332(15):1282-1295.

[51] Girard TD, Self WH, Edwards KM, Grijalva CG, Zhu Y, Williams DJ, et al. Long-term cognitive tmpairment after hospitalization for community-acquired pneumonia: A prospective cohort study. J Gen Intern Med 2018; 33(6):929-935.

[52] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200(7):e45-e67.

[53] Respiratory Branch of Chinese Geriatrics Society. Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition). Chin J Tuberc Respir Dis 2025; 48(1):18-34.

[54] Briggs S, Pearce R, Dilworth S, Higgins I, Hullick C, Attia J. Clinical pharmacist review: A randomised controlled trial. Emerg Med Australas 2015; 27(5):419-26.

[55] Jiang Y, Du ZQ, Zhu HH, Wang Q. Effect of pharmaceutical care on the treatment of community-acquired pneumonia in the elderly: A case report. Eur Rev Med Pharmacol Sci 2022; 26(16):5814-5820.

[56] Touchette DR, Masica AL, Dolor RJ, Schumock GT, Choi YK, Kim Y, et al. Safety-focused medication therapy management: A randomized controlled trial. J Am Pharm Assoc ( 2003) 2012; 52(5):603-612.

[57] Qin X, Ding L, Hao M, Li P, Hu F, Wang M. Antimicrobial resistance of clinical bacterial isolates in China: Current status and trends. JAC Antimicrob Resist 2024; 6(2):dlae052.

[58] Zhao F, Li J, Liu J, Guan X, Gong J, Liu L, et al. Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China. Antimicrob Resist Infect Control 2019;8:143.

[59] Jiang Y, Dou H, Xu B, Xu B, Zhou W, Wang H, et al. Macrolide resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019. Epidemiol Infect 2024;152:e75.

[60] Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019; 380(6):517-527.

[61] Tang HJ, Lai CC, Chao CM. The clinical efficacy of lefamulin in the treatment of elderly patients with community-acquired bacterial pneumonia. J Thorac Dis 2020; 12(8):4588-4590.

[62] Alexander E, Goldberg L, Das AF, Moran GJ, Sandrock C, Gasink LB, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: The LEAP 2 randomized clinical trial. JAMA 2019; 322(17):1661-1671.

[63] File TM Jr, Alexander E, Goldberg L, Das AF, Sandrock C, Paukner S, et al. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities. BMC Pulm Med 2021; 21(1):154.

[64] Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis 2019; 68(9):1482-1493.

[65] Ramirez JA, Chandler TR, Furmanek SP, Carrico R, Wilde AM, Sheikh D, et al. Community-acquired pneumonia in the immunocompromised host: Epidemiology and outcomes. Open Forum Infect Dis 2023; 10(11):ofad565.

[66] Wu X, Sun T, Cai Y, Zhai T, Liu Y, Gu S, et al. Clinical characteristics and outcomes of immunocompromised patients with severe community-acquired pneumonia: A single-center retrospective cohort study. Front Public Health 2023;11:1070581.

[67] Bidell MR, Lodise TP. Suboptimal clinical response rates with newer antibiotics among patients with moderate renal impairment: Review of the literature and potential pharmacokinetic and pharmacodynamic considerations for observed findings. Pharmacotherapy 2018; 38(12):1205-1215.

[68] Gu S, Rajendiran G, Forest K, Tran TC, Denny JC, Larson EA, et al. Drug-induced liver injury with commonly used antibiotics in the all of us research program. Clin Pharmacol Ther 2023; 114(2):404-412.

[69] Expert group of antimicrobial dosing optimization during continuous renal replacement therapy, Chinese Pharmaceutical Association Hospital Pharmacy Professional Committee, Infectious Diseases Society of China. Expert consensus on antimicrobial dosing optimization during continuous renal replacement therapy ( 2024). Chin J Nephrol 2024; 40(2):158-174.

[70] Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50(2):99-110.

[71] Kovacevic T, Miljkovic B, Mikov M, Stojisavljevic Satara S, Dragic S, Momcicevic D, et al. The effect of hypoalbuminemia on the therapeutic concentration and dosage of vancomycin in critically ill septic patients in low-resource countries. Dose Response 2019; 17(2):1559325819850419.

[72] T’jollyn H, Vermeulen A, Van Bocxlaer J, Colin P. A physiologically based pharmacokinetic perspective on the clinical utility of albumin-based dose adjustments in critically ill patients. Clin Pharmacokinet 2018; 57(1):59-69.

[73] Cantarutti A, Rea F, Franchi M, Beccalli B, Locatelli A, Corrao G. Use of antibiotic treatment in pregnancy and the risk of several neonatal outcomes: A population-based study. Int J Environ Res Public Health 2021; 18(23):12621.

[74] Rac H, Gould AP, Eiland LS, Griffin B, Mclaughlin M, Stover KR, et al. Common bacterial and viral infections: Review of management in the pregnant patient. Ann Pharmacother 2019; 53(6):639-651.